Literature DB >> 19756861

Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver.

Joseph P Erinjeri1, Ajita Deodhar, Raymond H Thornton, Peter J Allen, George I Getrajdman, Karen T Brown, Constantinos T Sofocleous, Diane L Reidy.   

Abstract

Hepatic encephalopathy is considered a contraindication to hepatic artery embolization. We describe a patient with a well-differentiated neuroendocrine tumor metastatic to the liver with refractory hepatic encephalopathy and normal liver function tests. The encephalopathy was refractory to standard medical therapy with lactulose. The patient's mental status returned to baseline after three hepatic artery embolization procedures. Arteriography and ultrasound imaging before and after embolization suggest that the encephalopathy was due to arterioportal shunting causing hepatofugal portal venous flow and portosystemic shunting. In patients with a primary or metastatic well-differentiated neuroendocrine tumor whose refractory hepatic encephalopathy is due to portosystemic shunting (rather than global hepatic dysfunction secondary to tumor burden), hepatic artery embolization can be performed safely and effectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756861      PMCID: PMC5635822          DOI: 10.1007/s00270-009-9698-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  26 in total

1.  Hepatic encephalopathy due to portal venous thrombosis in a patient with pancreatic tumor.

Authors:  Takatsugu Yamamoto; Yasushi Kuyama; Kazuo Takeuchi; Natsuko Nagashima; Hajime Honjo; Norio Sakurai; Chikao Okuda
Journal:  Pancreas       Date:  2003-04       Impact factor: 3.327

2.  HEPATIC COMA DUE TO LIVER METASTASES.

Authors:  N R PAL; G E WHITTINGHAM; R G PALEY
Journal:  Br Med J       Date:  1965-01-16

3.  Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.

Authors:  Daniel B Brown; Jean-Francois H Geschwind; Michael C Soulen; Steven F Millward; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2006-02       Impact factor: 3.464

4.  Portal hemodynamics in patients with hepatocellular carcinoma.

Authors:  F Moriyasu; N Ban; O Nishida; T Nakamura; Y Soh; K Miura; M Sakai; T Miyake; H Uchino
Journal:  Radiology       Date:  1986-12       Impact factor: 11.105

5.  Hepatic encephalopathy secondary to transtumoral portal-hepatic venous shunting.

Authors:  Baljendra S Kapoor; David W Hunter; Edward Greeno; Stefan Pambuccian; Timothy Sielaff
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

Review 6.  Updated treatment approach to hepatocellular carcinoma.

Authors:  Josep M Llovet
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

Review 7.  The hyperdynamic circulation in cirrhosis: an overview.

Authors:  L Blendis; F Wong
Journal:  Pharmacol Ther       Date:  2001-03       Impact factor: 12.310

8.  Metastatic carcinoid tumour presenting as hepatic encephalopathy.

Authors:  Alexander Stojadinovic; Peter J Allen; Craig D Shriver
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

Review 9.  Chemoembolization of hepatocellular carcinoma.

Authors:  Douglas E Ramsey; Lily Y Kernagis; Michael C Soulen; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

10.  Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy.

Authors:  Beatriz Mínguez; Juan Carlos García-Pagán; Jaume Bosch; Juan Turnes; Juli Alonso; Alex Rovira; Juan Córdoba
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

View more
  5 in total

Review 1.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

2.  Transarterial embolization of hypervascular tumors using trisacryl gelatin microspheres (Embosphere): a prospective multicenter clinical trial in Japan.

Authors:  Keigo Osuga; Yasuo Nakajima; Miyuki Sone; Yasuaki Arai; Yoshihiro Nambu; Shinichi Hori
Journal:  Jpn J Radiol       Date:  2016-03-10       Impact factor: 2.374

3.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

Review 4.  Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.

Authors:  Roberto Ronca; Patrizia Benzoni; Angela De Luca; Elisabetta Crescini; Patrizia Dell'Era
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

5.  Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver.

Authors:  Huanzhang Niu; Tingwei Du; Quanping Xiao; Xin Hu; Dongmin Li; Chao Wang; Wanqin Gao; Taohong Xing; Xiangmei Xu
Journal:  Oncotarget       Date:  2017-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.